--- title: "Capital allocation, Penghua CSI Chinese Medicine ETF net subscription of 36.5 million units, policies continuously improving to support the development of traditional Chinese medicine" type: "News" locale: "en" url: "https://longbridge.com/en/news/282501355.md" description: "Penghua CSI Chinese Medicine ETF net subscribed 36.5 million units, and the State Administration for Market Regulation approved three national standards in the field of acupuncture, which will be implemented starting October 1. Zhongtai Securities analysis pointed out that the reform of medical insurance payment promotes the construction of the clinical value evaluation system for traditional Chinese medicine, and traditional Chinese medicine products with RCT evidence chains are more likely to gain access to medical insurance. The performance of the CSI Traditional Chinese Medicine Index constituent stocks was poor, with BUCHANG PHARMA leading the decline at 3.17%. Penghua CSI Chinese Medicine ETF closely tracks the CSI Traditional Chinese Medicine Index, reflecting the overall performance of listed companies in the traditional Chinese medicine concept" datetime: "2026-04-13T07:14:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282501355.md) - [en](https://longbridge.com/en/news/282501355.md) - [zh-HK](https://longbridge.com/zh-HK/news/282501355.md) --- # Capital allocation, Penghua CSI Chinese Medicine ETF net subscription of 36.5 million units, policies continuously improving to support the development of traditional Chinese medicine In terms of news, the State Administration for Market Regulation has approved the release of three recommended national standards in the field of acupuncture: "Acupuncture Technique Operation Specification Part 4: Three-edged Needle" (GB/T 21709.4—2026), "Handling of Abnormal Situations in Acupuncture" (GB/T 33415—2026), and "Medication Specification for Acupoint Application" (GB/T 33414—2026). These three standards were organized and revised by the National Administration of Traditional Chinese Medicine and will officially be implemented starting October 1. Zhongtai Securities analysis believes that against the backdrop of deepening medical insurance payment reform, the clinical value evaluation system for traditional Chinese medicine is accelerating its construction. Traditional Chinese medicine products with RCT evidence chains, real-world data support, and clear mechanisms of action are more likely to gain medical insurance access and clinical promotion. Currently, several new traditional Chinese medicine drugs have been approved through the "three-in-one" review path, covering fields such as cardiovascular and cerebrovascular diseases and the digestive system. Additionally, multiple pilot programs have included traditional Chinese medicine decoction pieces and hospital preparations in DRG exclusion payments, systematically improving the clinical use ecology of traditional Chinese medicine. As of April 13, 2026, 14:59, in terms of the components of the CSI Traditional Chinese Medicine Index (930641), BUCHANG PHARMA led the decline at 3.17%, Jichuan Pharmaceutical fell by 3.06%, Panlong Pharmaceutical dropped by 2.88%, Zhenbaodao decreased by 2.64%, and Jinghua Pharmaceutical fell by 2.61%. The latest quote for the traditional Chinese medicine ETF Penghua (159647) is 0.93 yuan, with a net subscription of 36.5 million shares today. The traditional Chinese medicine ETF Penghua closely tracks the CSI Traditional Chinese Medicine Index, which selects the securities of listed companies involved in the production and sales of traditional Chinese medicine as samples to reflect the overall performance of listed companies in the traditional Chinese medicine concept. Data shows that as of March 31, 2026, the top ten weighted stocks in the CSI Traditional Chinese Medicine Index (930641) are Yunnan Baiyao, Pian Zai Huang, Dong'e Ejiao, Tongrentang, China Resources Sanjiu, Jilin Aodong, Baiyunshan, Yiling Pharmaceutical, Zhongsheng Pharmaceutical, and Darentang, with the top ten weighted stocks accounting for a total of 55.08%. The traditional Chinese medicine ETF Penghua (159647) has off-market connections (A: 016891; C: 016892; I: 022881) ### Related Stocks - [159647.CN](https://longbridge.com/en/quote/159647.CN.md) - [603858.CN](https://longbridge.com/en/quote/603858.CN.md) - [165519.CN](https://longbridge.com/en/quote/165519.CN.md) ## Related News & Research - [Worried About a Market Crash? 3 Vanguard ETFs Built to Survive](https://longbridge.com/en/news/286880525.md) - [South Korean funeral company reveals $33 million loss on leveraged ether ETF bet](https://longbridge.com/en/news/287088714.md) - [$100 Invested In iShares S&P 500 Growth ETF 20 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/286800978.md) - [If You Invested $1000 In Fidelity MSCI Energy Index ETF Stock 5 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/287254135.md) - [$1000 Invested In Vanguard S&P 500 Growth ETF 15 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/286797286.md)